Abstract
The KAART Trial: a randomized controlled trial of HAART compared to the combination of HAART and \chemotherapy in treatment-naive patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa A Mosam, F Shaik, TS Uldrick, GH Friedland, DT Scadden, J Aboobaker, HM Coovadia From 12 International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 26-27 April, 2010
Highlights
KS is the most common cancer in people with HIV/ AIDS, affecting both men and women in sub-Saharan Africa
The KAART Trial: a randomized controlled trial of HAART compared to the combination of HAART and \chemotherapy in treatment-naïve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa
Given poor access to HAART and prevalent HIV and KS-associated herpesvirus co-infection, advanced HIV-KS is an increasing problem in KZN. This is the first prospective study evaluating the impact of HAART and the role of early chemotherapy in HIV-KS in Africa
Summary
KS is the most common cancer in people with HIV/ AIDS, affecting both men and women in sub-Saharan Africa. The KAART Trial: a randomized controlled trial of HAART compared to the combination of HAART and \chemotherapy in treatment-naïve patients with HIV-associated Kaposi sarcoma (HIV-KS) in KwaZulu-Natal (KZN), South Africa From 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. Background KS is the most common cancer in people with HIV/ AIDS, affecting both men and women in sub-Saharan Africa.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
